{
  "trial_id": "NCT02000427",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, ECOG performance status, percentage of blasts in bone marrow, prior treatment with tyrosine kinase inhibitors (TKIs), history of allogeneic hematopoietic stem cell transplantation (HSCT), presence of active graft-versus-host disease (GvHD), history of central nervous system (CNS) pathology, presence of active CNS or testicular disease, history of autoimmune disease, prior malignancy history.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Prior Tyrosine Kinase Inhibitor (TKI) Treatment",
          "prior treatment with tyrosine kinase inhibitors (TKIs)"
        ],
        [
          "Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",
          "history of allogeneic hematopoietic stem cell transplantation (HSCT)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Number of Prior Relapses",
        "Number of Prior Salvage Regimens",
        "Time From Initial Diagnosis"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "percentage of blasts in bone marrow",
        "presence of active graft-versus-host disease (GvHD)",
        "history of central nervous system (CNS) pathology",
        "presence of active CNS or testicular disease",
        "history of autoimmune disease",
        "prior malignancy history."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Percentage of blasts in bone marrow, Prior treatment with tyrosine kinase inhibitors, Time since last chemotherapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Prior Tyrosine Kinase Inhibitor (TKI) Treatment",
          "Prior treatment with tyrosine kinase inhibitors"
        ]
      ],
      "remaining_reference_features": [
        "Number of Prior Relapses",
        "Number of Prior Salvage Regimens",
        "Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",
        "Time From Initial Diagnosis"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG performance status",
        "Percentage of blasts in bone marrow",
        "Time since last chemotherapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "##Answer:\nAge, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Bone Marrow Blasts, Prior Tyrosine Kinase Inhibitor Therapy, Prior Imatinib Mesylate Therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Prior Tyrosine Kinase Inhibitor (TKI) Treatment",
          "Prior Tyrosine Kinase Inhibitor Therapy"
        ]
      ],
      "remaining_reference_features": [
        "Number of Prior Relapses",
        "Number of Prior Salvage Regimens",
        "Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",
        "Time From Initial Diagnosis"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG Performance Status",
        "Bone Marrow Blasts",
        "Prior Imatinib Mesylate Therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, number of prior therapies, prior TKI therapy, time since initial diagnosis, time since relapse, bone marrow blast percentage, peripheral blood blast percentage, white blood cell count, hemoglobin level, platelet count, lactate dehydrogenase level, creatinine level, bilirubin level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Prior Tyrosine Kinase Inhibitor (TKI) Treatment",
          "prior TKI therapy"
        ],
        [
          "Number of Prior Relapses",
          "number of prior therapies"
        ],
        [
          "Prior Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",
          "prior TKI therapy"
        ],
        [
          "Time From Initial Diagnosis",
          "time since initial diagnosis"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Number of Prior Salvage Regimens"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "ECOG performance status",
        "time since relapse",
        "bone marrow blast percentage",
        "peripheral blood blast percentage",
        "white blood cell count",
        "hemoglobin level",
        "platelet count",
        "lactate dehydrogenase level",
        "creatinine level",
        "bilirubin level"
      ]
    }
  }
}